1) Lentivector Gene Therapy for X-linked Severe Combined Immune Deficiency (XSCID) in Older Children, Young Adults with Impaired Immunity 2) A New Approach to Cancer Immunotherapy Targeting Unique Cancer Mutations
Lentivector Gene Therapy for X-linked Severe Combined Immune Deficiency (XSCID) in Older Children, Young Adults with Impaired Immunity and Recurrent Infections Despite Prior Haplo-transplant
Harry L. Malech, MD
Chief, Laboratory of Host Defenses and
Chief, Genetic Immunotherapy Section, NIAID
A New Approach to Cancer Immunotherapy Targeting Unique Cancer Mutations
Steven A. Rosenberg, MD, PhD
Chief, Surgery Branch, NCI
For more information go to http://www.cc.nih.gov/about/news/grcurrent.htmlAir date: 9/30/2015 12:00:00 PM
Source: Videocast - All Events - Category: Journals (General) Tags: Upcoming Events Source Type: video
More News: Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Children | Gene Therapy | General Medicine | Genetics | Immunotherapy | Laboratory Medicine | Transplant Surgery | Transplants